Psychiatric Adverse Drug Reactions and Potential Anti-COVID-19 Drug Interactions with Psychotropic Medications

AuthorParisa Ghasemiyehen
AuthorNegar Mortazavien
AuthorIman Karimzadehen
AuthorAfsaneh Vazinen
AuthorLaleh Mahmoudien
AuthorEbrahim Moghimi-Saranien
AuthorAshkan MohammadSadeghien
AuthorMina Shahisavandien
AuthorAli Kheradmanden
AuthorSoliman Mohammadi-Samanien
Issued Date2021-07-31en
AbstractCoronavirus disease 2019 (COVID-19) management in patients with predisposing psychiatric disorders would be challenging due to potential drug-drug interactions (PDDIs) and precipitation of their disease severity. Furthermore, COVID-19 itself might precipitate or induce unpredicted psychiatry and neuropsychiatry complications in these patients. In this literature review study, the psychological impacts of COVID-19 and major psychiatric adverse drug reactions (ADRs) of COVID-19 treatment options have been discussed. A detailed Table has been provided to assess potential drug-drug interactions of COVID-19 treatment options with psychotropic medications to avoid unwanted major drug-drug interactions. Finally, potential mechanisms of these major drug-drug interactions and possible management of them have been summarized. The most common type of major PDDIs is pharmacokinetics. Hydroxychloroquine/chloroquine and lopinavir/ritonavir were the most involved anti-COVID-19 agents in these major PDDIs.en
DOIhttps://doi.org/10.22037/ijpr.2021.114717.15007en
KeywordCOVID-19en
KeywordPsychotropic medicationen
KeywordAdverse drug reactionsen
KeywordDrug-drug interactionsen
KeywordPharmacokineticsen
PublisherBrieflandsen
TitlePsychiatric Adverse Drug Reactions and Potential Anti-COVID-19 Drug Interactions with Psychotropic Medicationsen
TypeReview Article_importeden

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijpr-20-66.pdf
Size:
373.41 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF